

# Nor Eddine Sounni

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2376784/publications.pdf>

Version: 2024-02-01

47  
papers

3,362  
citations

186265

28  
h-index

243625

44  
g-index

49  
all docs

49  
docs citations

49  
times ranked

5692  
citing authors

#	ARTICLE	IF	CITATIONS
1	Laser-induced choroidal neovascularization model to study age-related macular degeneration in mice. <i>Nature Protocols</i> , 2013, 8, 2197-2211.	12.0	283
2	Targeting the Tumor Microenvironment for Cancer Therapy. <i>Clinical Chemistry</i> , 2013, 59, 85-93.	3.2	280
3	Tyrosine Kinase Inhibitors in Cancer: Breakthrough and Challenges of Targeted Therapy. <i>Cancers</i> , 2020, 12, 731.	3.7	280
4	MT1-MMP expression promotes tumor growth and angiogenesis through an up-regulation of vascular endothelial growth factor expression. <i>FASEB Journal</i> , 2002, 16, 555-564.	0.5	234
5	Anti-Invasive, Antitumoral, and Antiangiogenic Efficacy of a Pyrimidine-2,4,6-trione Derivative, an Orally Active and Selective Matrix Metalloproteinases Inhibitor. <i>Clinical Cancer Research</i> , 2004, 10, 4038-4047.	7.0	148
6	Blocking Lipid Synthesis Overcomes Tumor Regrowth and Metastasis after Antiangiogenic Therapy Withdrawal. <i>Cell Metabolism</i> , 2014, 20, 280-294.	16.2	141
7	Membrane type-matrix metalloproteinases and tumor progression. <i>Biochimie</i> , 2005, 87, 329-342.	2.6	127
8	Up-regulation of Vascular Endothelial Growth Factor-A by Active Membrane-type 1 Matrix Metalloproteinase through Activation of Src-Tyrosine Kinases. <i>Journal of Biological Chemistry</i> , 2004, 279, 13564-13574.	3.4	126
9	Membrane type-1 matrix metalloproteinase and TIMP-2 in tumor angiogenesis. <i>Matrix Biology</i> , 2003, 22, 55-61.	3.6	116
10	Tumor resistance to ferroptosis driven by Stearoyl-CoA Desaturase-1 (SCD1) in cancer cells and Fatty Acid Biding Protein-4 (FABP4) in tumor microenvironment promote tumor recurrence. <i>Redox Biology</i> , 2021, 43, 102006.	9.0	102
11	Stromal integrin $\alpha 11$ regulates PDGFR $\beta$ signaling and promotes breast cancer progression. <i>Journal of Clinical Investigation</i> , 2019, 129, 4609-4628.	8.2	102
12	Membrane associated proteases and their inhibitors in tumour angiogenesis. <i>Journal of Clinical Pathology</i> , 2004, 57, 577-584.	2.0	96
13	Epigenetic Control of the Invasion-promoting MT1-MMP/MMP-2/TIMP-2 Axis in Cancer Cells. <i>Journal of Biological Chemistry</i> , 2009, 284, 12727-12734.	3.4	95
14	New and Paradoxical Roles of Matrix Metalloproteinases in the Tumor Microenvironment. <i>Frontiers in Pharmacology</i> , 2012, 3, 140.	3.5	88
15	BRCAness, SLFN11, and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancers. <i>Science Translational Medicine</i> , 2020, 12, .	12.4	86
16	Membrane Type 1 Matrix Metalloproteinase-associated Degradation of Tissue Inhibitor of Metalloproteinase 2 in Human Tumor Cell Lines. <i>Journal of Biological Chemistry</i> , 2000, 275, 11368-11378.	3.4	84
17	Stromal regulation of vessel stability by MMP14 and TGF $\beta 2$ . <i>DMM Disease Models and Mechanisms</i> , 2010, 3, 317-332.	2.4	82
18	MT-MMPS as Regulators of Vessel Stability Associated with Angiogenesis. <i>Frontiers in Pharmacology</i> , 2011, 2, 111.	3.5	64

#	ARTICLE	IF	CITATIONS
19	Membrane-Type 4 Matrix Metalloproteinase Promotes Breast Cancer Growth and Metastases. <i>Cancer Research</i> , 2006, 66, 5165-5172.	0.9	61
20	Development of an optimized activatable MMP-14 targeted SPECT imaging probe. <i>Bioorganic and Medicinal Chemistry</i> , 2009, 17, 653-659.	3.0	61
21	Timp $\alpha$ 2 binding with cellular MT1 $\alpha$ MMP stimulates invasion $\alpha$ promoting MEK/ERK signaling in cancer cells. <i>International Journal of Cancer</i> , 2010, 126, 1067-1078.	5.1	57
22	Lymphangiogenesis in post-natal tissue remodeling: Lymphatic endothelial cell connection with its environment. <i>Molecular Aspects of Medicine</i> , 2011, 32, 146-158.	6.4	56
23	Sunitinib Inhibits Inflammatory Corneal Lymphangiogenesis. , 2013, 54, 3082.		55
24	New prospects in the roles of the C-terminal domains of VEGF-A and their cooperation for ligand binding, cellular signaling and vessels formation. <i>Angiogenesis</i> , 2013, 16, 353-371.	7.2	51
25	Expression of membrane type 1 matrix metalloproteinase (MT1-MMP) in A2058 melanoma cells is associated with MMP-2 activation and increased tumor growth and vascularization. <i>International Journal of Cancer</i> , 2002, 98, 23-28.	5.1	48
26	Capecitabine Efficacy Is Correlated with TYMP and RB1 Expression in PDX Established from Triple-Negative Breast Cancers. <i>Clinical Cancer Research</i> , 2018, 24, 2605-2615.	7.0	45
27	Expression of MT4-MMP, EGFR, and RB in Triple-Negative Breast Cancer Strongly Sensitizes Tumors to Erlotinib and Palbociclib Combination Therapy. <i>Clinical Cancer Research</i> , 2019, 25, 1838-1850.	7.0	41
28	Crystal Structure of the Catalytic Domain of MMP-16/MT3-MMP: Characterization of MT-MMP Specific Features. <i>Journal of Molecular Biology</i> , 2004, 336, 213-225.	4.2	37
29	Myoferlin targeting triggers mitophagy and primes ferroptosis in pancreatic cancer cells. <i>Redox Biology</i> , 2022, 53, 102324.	9.0	34
30	EGFR Activation and Signaling in Cancer Cells Are Enhanced by the Membrane-Bound Metalloprotease MT4-MMP. <i>Cancer Research</i> , 2014, 74, 6758-6770.	0.9	33
31	Degradomic and yeast 2-hybrid inactive catalytic domain substrate trapping identifies new membrane-type 1 matrix metalloproteinase (MMP14) substrates: CCN3 (Nov) and CCN5 (WISP2). <i>Matrix Biology</i> , 2017, 59, 23-38.	3.6	29
32	Towards Lipidomics of Low-Abundant Species for Exploring Tumor Heterogeneity Guided by High-Resolution Mass Spectrometry Imaging. <i>International Journal of Molecular Sciences</i> , 2013, 14, 24560-24580.	4.1	25
33	Rewiring of Lipid Metabolism and Storage in Ovarian Cancer Cells after Anti-VEGF Therapy. <i>Cells</i> , 2019, 8, 1601.	4.1	25
34	The proteolytic activity of MT4 $\alpha$ MMP is required for its pro $\alpha$ angiogenic and pro $\alpha$ metastatic promoting effects. <i>International Journal of Cancer</i> , 2012, 131, 1537-1548.	5.1	24
35	MT4-MMP: The GPI-Anchored Membrane-Type Matrix Metalloprotease with Multiple Functions in Diseases. <i>International Journal of Molecular Sciences</i> , 2019, 20, 354.	4.1	23
36	New Functions of Stromal Proteases and Their Inhibitors in Tumor Progression. <i>Surgical Oncology Clinics of North America</i> , 2001, 10, 417-432.	1.5	22

#	ARTICLE	IF	CITATIONS
37	Unimpeded skin carcinogenesis in K14 $\alpha$ -HPV16 transgenic mice deficient for plasminogen activator inhibitor. <i>International Journal of Cancer</i> , 2011, 128, 283-293.	5.1	15
38	Dynamics of internalization and recycling of the prometastatic membrane type 4 matrix metalloproteinase (MMP4) in breast cancer cells. <i>FEBS Journal</i> , 2016, 283, 704-722.	4.7	15
39	Dusp3 deletion in mice promotes experimental lung tumour metastasis in a macrophage dependent manner. <i>PLoS ONE</i> , 2017, 12, e0185786.	2.5	14
40	MT4-MMP and EGFR expression levels are key biomarkers for breast cancer patient response to chemotherapy and erlotinib. <i>British Journal of Cancer</i> , 2017, 116, 742-751.	6.4	13
41	Estetrol Combined to Progestogen for Menopause or Contraception Indication Is Neutral on Breast Cancer. <i>Cancers</i> , 2021, 13, 2486.	3.7	13
42	Biochemical evidence of the interactions of membrane type-1 matrix metalloproteinase (MT1-MMP) with adenine nucleotide translocator (ANT): potential implications linking proteolysis with energy metabolism in cancer cells. <i>Biochemical Journal</i> , 2009, 420, 37-47.	3.7	10
43	Microenvironment-derived ADAM28 prevents cancer dissemination. <i>Oncotarget</i> , 2018, 9, 37185-37199.	1.8	8
44	The timing of surgery after neoadjuvant radiotherapy influences tumor dissemination in a preclinical model. <i>Oncotarget</i> , 2015, 6, 36825-36837.	1.8	7
45	Molecular interactions involving urokinase plasminogen activator (uPA), its receptor (uPAR) and its inhibitor, plasminogen activator inhibitor-1 (PAI-1), as new targets for tumour therapy. <i>Expert Opinion on Therapeutic Targets</i> , 1999, 3, 469-481.	1.0	5
46	MO332 THE IRRADIATION-INDUCED RENAL ISCHEMIC PRECONDITIONING IS BLUNTED BY THE ORAL ADMINISTRATION OF THE ANTI-ANGIOGENIC AGENT, SUNITINIB. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, .	0.7	0
47	Exploration of MMP Function in Mouse Models of Angiogenesis. , 2011, , 105-115.		0